Concomitant gemcitabine (Gemzar®) and extended nodes irradiation in the treatment of pancreatic and biliary carcinoma: A phase I study

Onkologie

Volumn 26, Issue 4, 2003, Pages 325-329

  Morganti, A G ^a   Trodella, L ^a   Valentini, V ^a   Macchia, Gabriella ^a,b   Alfieri, S ^a   Smaniotto, D ^a   Luzi, S ^a   Costamagna, G ^a   Doglietto, G B ^a   Cellini, N ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

Biliopancreatic neoplasms; Chemoradiation; Dose escalation; Gemcitabine; Radiotherapy

Indexed keywords

AMINOTRANSFERASE; GEMCITABINE;

ABDOMINAL PAIN; ACUTE TOXICITY; ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; BEAM THERAPY; BILE DUCT CARCINOMA; BLOOD TOXICITY; CANCER RADIOTHERAPY; CANCER STAGING; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DEATH; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REGIMEN; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; GRANULOCYTOPENIA; HUMAN; INFUSION; LEUKOPENIA; LIVER FUNCTION TEST; LYMPH NODE; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; PANCREAS CARCINOMA; PHASE 1 CLINICAL TRIAL; SIDE EFFECT; STOMACH MUCOSA; STOMACH PAIN; TECHNIQUE; THROMBOCYTOPENIA; TREATMENT FAILURE;

AGED; BILE DUCT NEOPLASMS; COMBINED MODALITY THERAPY; COMMON BILE DUCT NEOPLASMS; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GALLBLADDER NEOPLASMS; HEPATIC DUCT, COMMON; HUMANS; INFUSIONS, INTRAVENOUS; KLATSKIN'S TUMOR; LYMPHATIC IRRADIATION; LYMPHATIC METASTASIS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PANCREATIC NEOPLASMS; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY, ADJUVANT;

EID: 10744228674     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000072089     Document Type: Article

References (22)

1. Wayne JD, Wolff RA, Pisters PWT, Evans DB: Multimodality management of localized pancreatic cancer. Cancer J 2001;7:S35-S46.
2. McGinn CJ, Zalupski MM: Combined-modality therapy in pancreatic carcinoma: Current status and future direction. Cancer J 2001;7:338-348.
3. Gastrointestinal Tumor Study Group: Treatment of locally unresectable carcinoma of the pancreas: Comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst 1988;80:751-755.
4. Moertel CG, Frytak S, Hanh RG, O'Connell MJ, Reitemeier RJ, Rubin J, Schutt AJ, Weiland LH, Childs DS, Holbrook MA, Lavin PT, Livstone E, Spiro H, Knowlton A, Kalser M, Barkin J, Lessner H, Mann-Kaplan R, Ramming K, Douglas HO Jr., Thomas P, Nave H, Bateman J, Lokich J, Brooks J, Chaffey J, Corson JM, Zamcheck N, Novak JW: Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-Fluorouracil) and high dose radiation + 5-Fluorouracil. Cancer 1981;48:1705-1710.
5. Foo ML, Gunderson LL, Bender CE, Buskirk SJ: External radiation therapy and transcatheter iridium in the treatment of extrahepatic bile duct carcinoma. Int J Radiat Oncol Biol Phys 1997;39:929-935.
6. Morganti AG, Trodella L, Valentini V, Montemaggi P, Costamagna G, Smaniotto D, Luzi S, Ziccarelli PP, Macchia G, Perri V, Mutignani M, Cellini N: Combined modality treatment in unresectable extrahepatic biliary carcinoma. Int J Radiat Oncol Biol Phys 2000;46:913-919.
7. McMaster KM, Tuttle TM, Leach SD, Rich T, Cleary KR, Evans DB, Curley SA: Neoadjuvant chemoradiation for extrahepatic cholangiocarcinoma. Am J Surg 1997;174:605-608.
8. Ben-Josef E, Vaishampayan UN, Vaitkevicius VK, Levin KJ, Philip P, Shields AF: A single institution experience with concurrent capecitabine and radiation therapy in gastrointestinal malignancies. Proc ASCO 2001;2329.
9. Moore TA, Iannitti D, DiPetrillo T, Rich T, Ramdin N, Cruff D, Quirk D, Akerman P, Cioffi W, Vakharia J, Robidoux H, Theall K, Nadeem A, Safran H: Gemcitabine, paclitaxel and radiation for locally advanced pancreatic cancer: A phase I trial. Proc ASCO 2001;2329.
10. Martenson JA, Vigliotti AG, Geeraerts LH, Sargent DJ, Ghosh C, Tschetter LK, Ebbert L: Phase I study of twice weekly gemcitabine (GEM) and cisplatin (CDDP) during radiation therapy (RT) for advanced pancreas and gastric cancer: A progress report. Proc ASCO 2001;2305.
11. Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 1997;15:2403-2413.
12. Lawrence T: Gemcitabine as a radiation sensitizer. Semin Oncol 1995;22:68-71.
13. Crane CH, Janjan NA, Evans DB, Wolff RA, Ballo MT, Milas L, Mason K, Charnsangavej C, Pisters PW, Lee JE, Lenzi R, Vauthey JN, Wong A, Phan T, Nguyen Q, Abbruzzese JL: Toxicity and efficacy of concurrent gemcitabine and radiotherapy for locally advanced pancreatic cancer. Int J Pancreatol 2001;29:9-18.
14. Hoffman J, McGinn C, Ross E: A phase I trial of preoperative gemcitabine and radiotherapy followed by postoperative gemcitabine for patients with localized, resectable, pancreatic adenocarcinoma. Cancer Invest 1999;17:30-32.
15. Talamonti MS, Catalano PJ, Vaughn DJ, Whittington R, Beauchamp RD, Berlin J, Benson AB 3rd: Eastern Cooperative Oncology Group Phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer: A regimen with unexpected early toxicity. J Clin Oncol 2000;18:3384-3389.
16. Blackstock AW, Bernard SA, Richards F, Eagle KS, Case LD, Poole ME, Savage PD, Tepper JE: Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer. J Clin Oncol 1999;17:2208-2212.
17. Kundrimoti M, Regine W, John W, Hanna N, Mohiuddin M: Concurrent infusional gemcitabine and radiation in the treatment of advanced unresectable GI malignancy: A phase I/II study. Proc ASCO 1999;928.
18. Mason KA, Milas L, Hunter NR, Elshaikh M, Buchmiller L, Kishi K, Hittelman K, Ang KK: Maximizing therapeutic gain with gemcitabine and fractionated radiation. Int J Radiat Oncol Biol Phys 1999;44:1125-1135.
19. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 1981;47:207-214.
20. Zalupski MM, Shields AF, Philip PA, Kraut M, LoRusso P, Heilbrun LK, Vaitkevicius V: Evaluation of pyrazoloacridine in patients with advanced pancreatic carcinoma. Invest New Drugs 1998;16:93-96.
21. Ikeda M, Okada S, Tokuuye K, Ueno H, Okusaka T: A phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with locally advanced pancreatic cancer. Br J Cancer 2002;86:1551-1554.
22. Phan TO, Crane CH, Janjan NA, Vrdoljak E, Milas L, Mason KA. WR-2721 reduces intestinal toxicity from concurrent gemcitabine and radiation treatment. Int J Pancreatol 2001;29:19-23.